Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4 study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms (FLS)…
- Trial name
- RELIEF (NCT02064816)
- Testing
- Rebif®
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Stroke, Traumatic Brain Injury
Validation of an Obstacle Course Used in Patients With Muscle Tightness
This study is being conducted to compare healthy patients versus patients with muscle tightness in their leg(s) after an acquired brain injury using walking trials time, a balance test, and foot pressure data.
- Conditions
- Stroke, Traumatic Brain Injury, Multiple Sclerosis, Spasticity
- Trial name
- NCT00776048
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Multiple Sclerosis
Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)
This will be prospective, multicentre, observational study. Patients who will initiate treatment with IFNβ-1b (Betaferon) will be followed up to 6 months. Baseline visit (visit 0) i.e.
- Trial name
- INFLUENCE (NCT01706055)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- Poland
- Volunteers
- 629 people
- Sponsor
- Bayer
Relapsing Multiple Sclerosis
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.
- Trial name
- NCT07211633
- Testing
- Ublituximab
- Where
- 48 sites in Bosnia and Herzegovina, Bulgaria and 7 more
- Volunteers
- 360 people
- Sponsor
- TG Therapeutics, Inc.
Multiple Sclerosis, Healthy
Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation
In this study, lymph fluid will be collected by cannulation of the thoracic duct, a minimally invasive procedure performed by interventional radiologists.
- Trial name
- NCT05162638
- Testing
- thoracic duct cannulation
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Neuropathic Pain, Multiple Sclerosis
Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain
This is a comparative drug trial involving patients with clinically definite Multiple Sclerosis and documented neuropathic pain. Patients will be randomized to receive treatment with either paroxetine or pregabalin.
- Trial name
- NCT00291148
- Testing
- paroxetine, pregabalin
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- University of Manitoba
Multiple Sclerosis
Virtual Reality and Robot Assisted Gait Training in Patients With Multiple Sclerosis
Multiple Sclerosis (MS), the most common non-traumatic cause of neurologic disability in young adults, affects mobility and ambulation in the majority of patients.
- Trial name
- GE-O-VR (NCT02896179)
- Testing
- Robot-assisted gait training group+VR, GEO
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Universita di Verona
Multiple Sclerosis
How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?
Introduction: Multiple sclerosis (MS) is characterized by decreased strength and motor control, and compromised gait function. Reduced walking speed, balance, and fatigue are the cardinal symptoms.
- Trial name
- NCT02870023
- Testing
- Balance training, Strength training
- Where
- Denmark
- Volunteers
- 71 people
- Sponsor
- University of Aarhus
Multiple Sclerosis, Relapsing-Remitting
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
This is a multicentric, double-blind, placebo-controlled, randomized, parallel group study to estimate the effect of minocycline as add-on to interferon beta-1a (IFN beta-1a) in subjects with relapsing-remitting multiple…
- Trial name
- RECYCLINE (NCT01134627)
- Testing
- Minocycline
- Where
- Denmark
- Volunteers
- 305 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients
The investigators are measuring the adherence rates of an oral MS drug that is to be administered twice-daily. The investigators would like to observe any patterns that might indicate factors that greatly affect adherence.
- Trial name
- ADIMS (NCT02099370)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of South Florida
Multiple Sclerosis (MS)
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
SEPROS is a non-interventional study, based on primary data collection of MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol.
- Trial name
- SEPROS (NCT06157086)
- Testing
- ofatumumab
- Where
- 49 sites in France
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
The primary aim of this study is to evaluate the impact of titration, analgesics, and 12 month telephone follow-up period from the B.E.T.A nurse program upon adherence to treatment with Betaseron in patients with a first clinical…
- Trial name
- START (NCT00461396)
- Testing
- Interferon-1beta (Betaseron, BAY86-5046)
- Where
- 19 sites in United States
- Volunteers
- 104 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing Remitting
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
The rationale of this study is to assess the safety profile, efficacy and adherence to Rebif® New Formulation in real life settings with a multinational approach, as well as the impact of this improved formulation (with regards…
- Trial name
- STAR (NCT01080027)
- Testing
- Rebif® New Formulation
- Where
- Greece
- Volunteers
- 254 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon
In this study researchers wanted to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with Betaferon using the myBETAapp which includes the elements to what extent taking medication…
- Trial name
- NCT03808142
- Testing
- myBETAapp, PEAK, Betaferon, BAY86-5046
- Where
- Germany
- Volunteers
- 79 people
- Sponsor
- Bayer
Shingles, Zoster
Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients
The purpose of this study is to provide evidence as to whether RZV is immunogenic with an acceptable safety profile in Multiple Sclerosis patients on anti-CD20 treatment.
- Trial name
- MSHINGVAX (NCT05596526)
- Testing
- recombinant zoster vaccine
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Prof Patrice Lalive
Multiple Sclerosis, Relapsing-Remitting
The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis
The aim of the study is to investigate reliability, validity, and responsiveness of the timed 360° turn test in patients with Multiple Sclerosis.
- Trial name
- NCT03718026
- Testing
- The timed 360° turn test
- Where
- Turkey (Türkiye)
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Gazi University
Radiologically Isolated Syndromes; Multiple Sclerosis
Comparison of Digital Biomarkers in Subjects With Radiologically Isolated Syndrome (RIS) and Multiple Sclerosis (MS) Patients With Clinically Normal Neurological Examination
Radiologically Isolated Syndrome (RIS) is the preclinical stage of Multiple Sclerosis (MS). It is the incidental discovery of white matter abnormalities on brain or spinal cord magnetic resonance imaging (MRI), whose shape…
- Trial name
- SPAM 3 (NCT07135752)
- Testing
- Precision assessment
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.
- Trial name
- COURAGE-ALS (NCT04944784)
- Testing
- Reldesemtiv
- Where
- 84 sites in United States, Australia and 14 more
- Volunteers
- 489 people
- Sponsor
- Cytokinetics
Relapsing-remitting Multiple Sclerosis, RRMS
POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with…
- Trial name
- NCT01051817
- Testing
- AIN457
- Where
- 16 sites in Czechia, Russia and 1 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
Randomized Double-Blind Efficacy and safety study of Autologous HB-adMSCs versus placebo for the treatment of Multiple Sclerosis. This study will be for 24 subjects with 6 infusions over a 52 week period.
- Trial name
- HBMS01 (NCT05116540)
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hope Biosciences Research Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.